BCTX
BriaCell Therapeutics Corp.$3.44 +0.03 (+0.88%)
Oct 23 4:00 PM ET · prev $3.41
Market cap
$29.7M
Nano cap
1 year
−74.4%
from $13.42 · Oct 27
30 days
−17.3%
from $4.16
52-week range
$2.74–13.42
−74% from high · low Jun 11
Avg volume 20D
77.6K
Sep 28 spike 293.4K
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
1
analyzed by SecBot
SecBot read MIXED 1 report · latest
Balance 0 bearish · 0 bullish · 1 neutral oldest → newest, height = score
Avg score ·High conf. 1/1
Price
Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.
No data for this timeframe.
- E May 6 FDA: BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Cl…
- E May 22 FDA: BriaCell Presentations Highlight Positive Clinical Data fo…
- E May 26 FDA: BriaCell Receives Positive Recommendation from Data Safety…
- E Jul 16 FDA: BriaCell Opens First Canadian Site – Sunnybrook – for Pivo…
- E Aug 5 FDA: BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Cl…
- X Aug 31 Short interest jumps 81.5% to 723.8K
- E Sep 14 FDA: Data Safety Monitoring Board (DSMB) Recommends Continuing…
Signal stack
Where each data set points today.
- InstitutionsMIXED
Q2 2026: 3 added (0 new), 1 trimmed or exited.
- TrendDOWNTREND
9% below its 50-day average.
Who's buying
13F· Q2 20260
new positions
0
exits
| Fund | Move | Value |
|---|---|---|
| UBS Group AG | DOUBLED | $141.4K |
| NATIONAL BANK OF CANADA /FI/ | DOUBLED | $5.8K |
| MORGAN STANLEY | TRIM | $3.3K |
| ROYAL BANK OF CANADA | DOUBLED | $1.0K |
| UBS Group AG | DOUBLED | $48.4K |
| Federation des caisses Desjardins du Quebec | TRIM | $1.7K |
| GROUP ONE TRADING LLC | NEAR_EXIT | $67.00 |
| MORGAN STANLEY | DOUBLED | $24.9K |
Quarterly 13F filings are due 45 days after each quarter ends.
The Street
last action Aug 2025Recent actions
| Date | Firm | Rating |
|---|---|---|
| Aug 27, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Apr 22, 2025 | HC Wainwright & Co. REITERATE | Buy |
| Feb 3, 2025 | HC Wainwright & Co. MAINTAIN | Buy |
| Dec 12, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Dec 3, 2024 | HC Wainwright & Co. REITERATE | Buy |
| Oct 3, 2024 | HC Wainwright & Co. REITERATE | Buy |
Earnings setup
Estimates| Period | EPS est. | Range | 30D rev. | Revenue |
|---|---|---|---|---|
| Current Q | — | — | — | $0.00 |
| Next Q | — | — | — | $0.00 |
| Current FY | — | — | — | $0.00 |
| Next FY | — | — | — | $0.00 |
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Recent
Sep 14, 2026
FDA
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Sep 8, 2026
Contract
BriaCell’s Pivotal Phase 3 Metastatic Breast Cancer Study Expands to Leading Cancer Center
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Aug 24, 2026
Press release
BriaCell Advances Personalized Melanoma Immunotherapy Vaccine Candidate, Bria-MEL+™
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 24, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Aug 5, 2026
FDA
BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 05, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Jul 16, 2026
FDA
BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer
PHILADELPHIA and VANCOUVER, British Columbia, July 16, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL) (TSX: BCT)…
Short side
FINRA· Oct 15, 2026🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 14, 2026 FDA
Data Safety Monitoring Board (DSMB) Recommends Continuing BriaCell’s Phase 3 Metastatic Breast Cancer Study
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2026 (GLOBE NEWSWIRE) -- BriaCell Therapeuti
Jun 30, 2026 Inst.
UBS Group AG — DOUBLED
43,642 shares ($141.4K)
Jun 30, 2026 Inst.
Jun 26, 2026 SEC NATIONAL BANK OF CANADA — DOUBLED
1,803 shares ($5.8K)
BriaCell Therapeutics Corp. disclosed the unaudited financial statements of its subsidiary BriaPro Therapeutics Corp…
8-K — Impact 2/10
Reddit
Recent posts
Fresh post, for subscribers
SecBot reports
1 filing · 0 bullish · 0 bearish · 1 neutralAll BCTX filing & press-release reports (1)
- 8-K reportJun 26, 2026